As shown in Figure 5a,b, the nutraceutical was able to synergize with the anti-diabetic therapeutic in inducing LNCaP and PC3 cell death, demonstrating great potential in both mono- and combination therapy when used to treat PTEN-null and Akt/HK2-overexpressing PCa. The gene discussed is PTEN; the disease is posterior cortical atrophy.